个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wei Jianyi[1,2] * ; Liu Shupeng[1,2] * ; Bian Yuexiang[1,2] * ; Li Lei[9] * ; Qian Biyun[11] ; Shen Zixuan[1,2] ; Zhang Yan[1,2] ; Abuduaini Adila[1,2] ; Dong Fuchen[1,2] ; Zhang Xin[1,2] ; Li Jinhui[1,2] ; Yu Yongpei[4] ; Zhang Weituo[5] ; Wang Jun[6] ; Zhai Wei[7] ; Song Qixiang[7] ; Zheng Yu[8] ; Pan Weihua[12] ; Yu Lanlan[4] ; Zhan Qimin[10] ; Zhang Ning[10] ; Zheng Junhua[7] ; Pan Shuming[3] ; Yao Chen[4] ; Li Hai[1,2] ;
机构： [1]Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine [2]NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), 1630 Dong Fang Road, Shanghai 200127, China. [3]Department of Emergency, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Yangpu District, Shanghai, China. [4]Peking University Clinical Research Institute, Peking University First Hospital, Beijing 100083, China. [5]Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [6]Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160 Pujian Rd, Pudong, Shanghai 200127, China. [7]Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [8]Department of Respiratory Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [9]Department of Otorhinolaryngology-Head & Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [10]Peking University - Yunnan Baiyao International Medical Research Center, Beijing, China. [11]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [12]Department of Pediatric Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出处：
DOI： 10.1038/s41598-024-75891-3

关键词： Cepharanthine COVID-19 Effectiveness Safety SARS-CoV-2

摘要：
Cepharanthine (CEP) is a natural remedy that potently inhibits SARS-CoV-2 activity both in vitro and in vivo. To evaluate the efficacy and safety of CEP compared with placebo in adults with asymptomatic or mild coronavirus disease 2019 (COVID-19), we conducted a proof-of-concept, double-blind, randomized, placebo-controlled trial. Patients were randomized to receive 120 mg/day of CEP, 60 mg/day CEP or placebo for 5 days. Main outcome was the time from randomization to negative nasopharyngeal swab and safety. Among 262 randomized participants, 188 completed the trial among group of 120 mg/day CEP (n = 65), 60 mg/day CEP (n = 68) and placebo (n = 55). Neither 120 mg/day or 60 mg/day CEP shortened the time to negative significantly compared with placebo. However, 60 mg/day CEP showed a slight trend (difference=-0.77 days, hazard ratio (HR) = 1.40, 95% CI 0.97-2.01, p = 0.072). In analysis of participants with good medication compliance, 60 mg/day CEP significantly shortened the time to negative (difference=-0.87 days, HR = 1.56, 95% CI 1.03-2.37, p = 0.035). Adverse events were not different among the three groups, and no serious adverse events occurred. In conclusion, treatment of asymptomatic or mild Covid-19 with 120 mg/day or 60 mg/day did not shorten the time to negative significantly. However, 60 mg/day CEP showed a slight trend which needs future confirmatory trials to validate. (NCT05398705).© 2024. The Author(s).

基金：
Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152213).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区：
出版当年[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine [2]NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), 1630 Dong Fang Road, Shanghai 200127, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine [2]NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), 1630 Dong Fang Road, Shanghai 200127, China.
推荐引用方式(GB/T 7714)：
Wei Jianyi,Liu Shupeng,Bian Yuexiang,et al.Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials[J].Scientific Reports.2025,15(1):3875.doi:10.1038/s41598-024-75891-3.
APA：
Wei Jianyi,Liu Shupeng,Bian Yuexiang,Li Lei,Qian Biyun...&Li Hai.(2025).Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials.Scientific Reports,15,(1)
MLA：
Wei Jianyi,et al."Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials".Scientific Reports 15..1(2025):3875

相关文献

[1]SURVEY OF THE SHORT-TERM SAFETY OF THE VERO CELL COVID-19 VACCINE AMONG CHINESE CITIZENS IN LESOTHO [2]93例危重新型冠状病毒肺炎患者临床特点回顾分析 [3]A compendium answering 150 questions on COVID-19 and SARS-CoV-2 [4]Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity [5]Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. [6]Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG [7]Multiple organ injury on admission predicts in-hospital mortality in patients with COVID-19 [8]新型冠状病毒感染:零售药店工作指导与防控策略专家共识 [9]COVID-19 causing death in a rheumatoid arthritis patient who retested positive for SARS-CoV-2 RNA: A case report [10]Computer Audition for Fighting the SARS-CoV-2 Corona Crisis-Introducing the Multitask Speech Corpus for COVID-19

资源点击量：25477 今日访问量：0 总访问量：1499 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)